Q-fever, a worldwide zoonosis, is caused by Coxiella burnetii and is named for a 1985 disease outbreak in Queensland, Australia.
Tests generally appear in the order most useful for common clinical situations
| Test name: CBC with Platelet Count and Automated Differential |
| ARUP #: 0040003 |
| Methodology: Automated Cell Count/Differential |
| Use: Order to differentiate bacterial from viral etiology |
| Test name: Aspartate Aminotransferase, Serum or Plasma |
| ARUP #: 0020007 |
| Methodology: Quantitative Enzymatic |
| Use: Order to rule out associated hepatitis |
| Test name: Coxiella burnetii (Q-Fever) Antibodies, IgG & IgM by IFA with Reflex to Titer |
| ARUP #: 2003102 |
| Methodology: Immunofluorescence Assay (Indirect Fluorescent Antibody) |
| Use: Confirm infectious agent as C. burnetii (Q-fever) in symptomatic patients If C. burnetii IgG and/or IgM antibodies are detected, titer will be added |
| Test name: Coxiella burnetii (Q-Fever) Antibody IgG, Phase I & II by IFA |
| ARUP #: 0050462 |
| Methodology: Semi-Quantitative Indirect Fluorescent Antibody |
| Use: Confirm infectious agent as C. burnetii (Q-fever) in symptomatic patients Recommend testing of acute and convalescent sera |
| Limitations: Initial testing may not be helpful; treatment should be based on clinical and other laboratory assessment |
| Test name: Coxiella burnetii (Q-Fever) Antibody IgG, Phase I by IFA |
| ARUP #: 0050463 |
| Methodology: Semi-Quantitative Indirect Fluorescent Antibody |
| Use: Monitor treatment success via titers Order to confirm chronic disease (eg, endocarditis) |
| Follow-up: Follow up titers to confirm effectiveness of therapy in chronic disease |
| Test name: Sedimentation Rate, Westergren (ESR) |
| ARUP #: 0040325 |
| Methodology: Visual Identification |
| Use: Use for patients with suspected chronic Q-fever |
| Test name: C-Reactive Protein |
| ARUP #: 0050180 |
| Methodology: Quantitative Immunoturbidimetry |
| Use: Use in clinical scenarios associated with inflammation (autoimmune disease, connective tissue disease, rheumatoid arthritis, or sepsis) Do not order for CVD risk assessment; use CRP high sensitivity |
| Test name: Urinalysis, Complete |
| ARUP #: 0020350 |
| Methodology: Reflectance Spectrophotometry/Microscopy |
| Use: Determine presence of hematuria in suspected glomerulonephritis |
| Test name: Antimicrobial Susceptibility - Bactericidal Assay |
| ARUP #: 0060204 |
| Methodology: Broth Microdilution |
| Comments: |
| Test name: Coxiella burnetii (Q-Fever) Antibody IgG, Phase II by IFA |
| ARUP #: 0050464 |
| Methodology: Semi-Quantitative Indirect Fluorescent Antibody |
| Comments: |